The effect of eHealth-based guided self help interventions for binge eating disorder : a meta-analysis of randomized controlled trials.

Eat DisordMay 5, 2025 (epub)
Clinical ResearchPsychiatry

Gülsüm Zekiye Tuncer, Metin Tuncer

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis pooled eight randomized controlled trials involving 1,575 people diagnosed with binge eating disorder (BED) or reporting BED symptoms. It assessed guided self-help interventions delivered through eHealth, including web-based and hybrid formats, with intervention lengths ranging from a single session to four months. Compared with control conditions, eHealth-guided self-help reduced binge-eating psychopathology (SMD: 0.53; 95% CI: 0.20-0.86) and objective binge-eating days (SMD: 0.49; 95% CI: 0.12-0.85).

Key findings

  • Across eight randomized trials, eHealth-guided self-help reduced binge-eating psychopathology versus controls (SMD: 0.53; 95% CI: 0.20-0.86).
  • Objective binge-eating days were also lower with eHealth-guided self-help (SMD: 0.49; 95% CI: 0.12-0.85).
  • Intervention duration ranged from a single session to four months; most studies evaluated web-based guided self-help.

Why it matters

The findings suggest that guided self-help delivered through digital platforms can improve key BED outcomes compared with control conditions. Such approaches may be relevant where access to traditional treatment is difficult, while the range of formats and intervention lengths indicates that the evidence covers varied implementations rather than one standardized program.

What to keep in mind

The trials varied in intervention duration and delivery format, and included people with either diagnosed BED or BED symptoms.

Source

Published in Eat Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.